Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


FDA Met Biosimilar Review Timelines But Missed Meeting Goals In 2015

Executive Summary

Agency's biosimilar meeting workload rose slightly; shifts in types of meetings may reflect maturation of individual biosimilar development programs.


Related Content

US Biosimilars: 40% First-Cycle Approval Rate Leaves Room For Improvement
Neulasta Biosimilar From Coherus Needs Better Immunogenicity Assay After Stumble At US FDA
US FDA Might Face Funding Penalty For Missing User Fee Goals
User Fees: Should US FDA Incur Penalties For Missed Deadlines?
US Generic Reviews: Would Pre-Submission Meetings Be Better Than Six-Month Priority Review?
US FDA Compliance Strategy: Meetings Replace Some Untitled Letters
Biosimilars Will Get PDUFA-Style Reviews Under New User Fee Plan
Biosimilar Barricade Breached: Amgen Manufacturing Patents Ruled Not Infringed
Biosimilar User Fee Talks Begin With Industry Negotiating Amongst Itself
As Biosimilar Meeting Requests Rise, So Do FDA's Performance Goal Challenges


Related Companies

Related Deals




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

All set! This Question has been sent to my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts